About
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a class of medication used to treat type 2 diabetes mellitus. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This mechanism lowers blood glucose levels independently of insulin secretion or sensitivity. Beyond its glucose-lowering effects, empagliflozin has demonstrated significant cardiovascular and renal benefits, including a reduction in the risk of cardiovascular death, heart failure hospitalization, and progression of kidney disease in patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease. It represents a crucial therapeutic option for comprehensive diabetes management.
Uses
- Management of type 2 diabetes mellitus.
- To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
- To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.
- To reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.
Directions For Use
Take this medication orally once daily in the morning, with or without food, as directed by your healthcare provider.
Benefits
- Effective blood glucose lowering.
- Reduces HbA1c levels.
- Proven cardiovascular benefits.
- Demonstrated renal protective effects.
- May lead to modest weight loss.
- Low risk of hypoglycemia when used alone.
Side Effects
- Urinary tract infections (UTIs)
- Genital yeast infections
- Increased urination
- Thirst
- Nausea
- Constipation
- Dizziness
- Hypotension (low blood pressure)
- Ketoacidosis (rare but serious)
- Kidney problems (acute kidney injury)
- Fournier's gangrene (very rare but serious)
- Allergic reactions
Safety Measures
- Alcohol - Excessive alcohol intake can increase the risk of dehydration and ketoacidosis, which are potential side effects of SGLT2 inhibitors. Use alcohol in moderation.
- Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development. Consult your doctor.
- Breastfeeding - It is unknown if empagliflozin is excreted in human milk. Due to potential risks to the infant, breastfeeding is not recommended while taking this medication.
- Liver - No dose adjustment is typically required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment as experience is limited.
- Kidney - Not recommended for initiation in patients with eGFR <30 mL/min/1.73m². Dose adjustment may be needed based on renal function. Monitor kidney function regularly.
- Lung - No specific contraindications related to lung conditions. However, conditions predisposing to dehydration should be managed carefully to avoid acute kidney injury.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!